The global estrogen and progesterone market is anticipated to grow at a considerable CAGR of 14.1% during the forecast period. The growing number of sex reassignment procedures performed globally is one of the major factors driving the growth of the estrogen and progesterone market. Such treatments provide functional abilities and physical appearance to the transgender with sexual characteristics they believe belong to. The increasing awareness and rising social acceptance of transgender, LGBT, and gay people will also give significant support to the estrogen and progesterone market during the forecast period. Additionally, supportive reimbursement policies in developed nations including the US, the UK, and Germany will also boost the number of sex reassignment procedures. Insurance companies including Aetna and Unicare provide insurance cover for such treatments.
Moreover, the rising prevalence of uterine bleeding, amenorrhea, breast cancer, and uterus cancer are also boosting the demand for estrogen and progesterone drugs. According to the Breast Cancer Foundation Organization, in 2020, there were over 684,996 mortality from breast cancer. Survival rates of breast cancer are high if the cancer is diagnosed at an early stage, however 80% of the breast cancers are diagnosed at an advanced stage. Thus, various foundations are supporting breast cancer-specific initiatives including The Breast Cancer Research Foundation. In October 2020, the Breast Cancer Foundation announced that it is funding $40 million for breast cancer research from 2020-2021. Additionally, BCRF’s 40% grants are for Metastatic breast cancer which funded 88 projects in 2020. These factors are driving the demand for estrogen and progesterone drugs globally.
However, the consumption of estrogen and progesterone has severe long-term side effects, such as headaches, mood swings, and back pain, among others, which will hamper the growth of the estrogen and progesterone market. This report will further analyze all the primary as well as secondary factors that are directly or indirectly impacting the growth of the market.
Various non-essential surgeries and treatments including sex reassignment treatment for the gender dysphoria patients were postponed during the COVID-19 pandemic. This had drastically reduced the demand for estrogen and progesterone drugs globally. The high cost associated with sex reassignment treatment is another major restraining factor for the market. The market is expected to show a U-shaped recovery after the COVID-19 situation gets normalized.
Segmental Outlook
The global estrogen and progesterone market is segmented based on the type and distribution channel. Based on the type, the market is segmented into aglepristone, mifepristone, asoprisnil, telapristone, and ulipristal acetate. Based on the distribution channel, the market is sub-segmented into pharmacy and hospital and clinics. Among these distribution channels, the hospital segment holds the major share in the market as it is the most trusted source for drug purchases among consumers. However, the pharmacy segment is expected to grow fastest during the forecast period owing to the rising trend of OTC drugs and attractive discounts offered by these pharmacies. The above-mentioned segments can also be customized as per the requirements.
Regional Outlooks
The global estrogen and progesterone market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). The market can also be analyzed for a particular region or country level as per the requirement.
Global Estrogen and Progesterone Market Growth by Region, 2022-2028
The North American Region Holds a Significant Share in the Global Estrogen and Progesterone Market
The North American region dominates the global estrogen and progesterone market owing to the rising number of sex reassignment surgeries performed in this region. According to the American Society of Plastic Surgeons, around 11,000 sex reassignment treatments were done in 2019 in the US. This was around 15% higher than in 2018. The European market is expected to grow fastest during the forecast period attributed to the legal acceptance of such treatments. Germany and the UK will be the major contributors to this growth due to the LGBT movement in the region.
Market Players Outlook
The major companies serving the global estrogen and progesterone market include AstraZeneca Ltd., Teva Pharmaceutical Industries Ltd., Abbott Healthcare Products B.V., Novartis International AG, Pfizer Inc., Merck Serono Ltd., and Bayer AG, among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance-
• Bayer AG announced the acquisition of KanDy Therapeutics Inc. in August 2020, which aids in the expansion of Bayer's women's drug pipeline by adding KanDy's menopause drug to its portfolio.
• Mankind Pharma launched the generic Dydrogesterone tablets for the treatment of infertility and pregnancy-related complications in the Indian market in December 2019. This was carried out to expand the treatment options and gain a competitive edge.
The Report Covers
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global Estrogen and Progesterone Market
• Recovery Scenario of Global Estrogen and Progesterone Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. AstraZeneca, Ltd.
3.1.1.1. Overview
3.1.1.2. Financial Analysis
3.1.1.3. SWOT Analysis
3.1.1.4. Recent Developments
3.1.2. Teva Pharmaceutical Industries, Ltd.
3.1.2.1. Overview
3.1.2.2. Financial Analysis
3.1.2.3. SWOT Analysis
3.1.2.4. Recent Developments
3.1.3. Abbott Healthcare Products B.V.
3.1.3.1. Overview
3.1.3.2. Financial Analysis
3.1.3.3. SWOT Analysis
3.1.3.4. Recent Developments
3.1.4. Novartis International AG
3.1.4.1. Overview
3.1.4.2. Financial Analysis
3.1.4.3. SWOT Analysis
3.1.4.4. Recent Developments
3.2. Key Strategy Analysis
4. Market Segmentation
4.1. Global Estrogen and Progesterone Market by Type
4.1.1. Aglepristone
4.1.2. Mifepristone
4.1.3. Asoprisnil
4.1.4. Telapristone
4.1.5. Ulipristal Acetate
4.2. Global Estrogen and Progesterone Market by Distribution Channel
4.2.1. Pharmacy
4.2.2. Hospital and Clinics
5. Regional Analysis
5.1. North America
5.1.1. US
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Aspen Pharmacare Australia Pty Ltd.
6.2. Bayer AG
6.3. Besins Healthcare Benelux
6.4. Bluebell pharma Group Co.
6.5. Dr.Kade Pharmazeutische Fabrik GmbH
6.6. Eli Lilly Nederland B.V.
6.7. F.I.S.-FABBRICA ITALIANA SINTETICI S.p.A.
6.8. Gedeon Richter Plc
6.9. Jenapharm GmbH & Co. KG
6.10. MERCK SERONO, Ltd.
6.11. N.V.Organon
6.12. Orion Corp.
6.13. Pfizer, Inc.
6.14. Shanghai Yijing Industrial Co., Ltd.
6.15. Sofgen Pharmaceuticals
6.16. Virtus Pharmaceuticals LLC
1. GLOBAL ESTROGEN AND PROGESTERONE MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL AGLEPRISTONE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL MIFEPRISTONE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL ASOPRISNIL MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL TELAPRISTONE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL ULIPRISTAL ACETATE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL ESTROGEN AND PROGESTERONE MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
8. GLOBAL ESTROGEN AND PROGESTERONE MARKET VIA PHARMACY RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL ESTROGEN AND PROGESTERONE MARKET VIA HOSPITAL AND CLINICS RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL ESTROGEN AND PROGESTERONE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11. GLOBAL ESTROGEN AND PROGESTERONE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
12. NORTH AMERICAN ESTROGEN AND PROGESTERONE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
13. NORTH AMERICAN ESTROGEN AND PROGESTERONE MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
14. NORTH AMERICAN ESTROGEN AND PROGESTERONE MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
15. EUROPEAN ESTROGEN AND PROGESTERONE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
16. EUROPEAN ESTROGEN AND PROGESTERONE MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
17. EUROPEAN ESTROGEN AND PROGESTERONE MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
18. ASIA-PACIFIC ESTROGEN AND PROGESTERONE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
19. ASIA-PACIFIC ESTROGEN AND PROGESTERONE MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
20. ASIA-PACIFIC ESTROGEN AND PROGESTERONE MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
21. REST OF THE WORLD ESTROGEN AND PROGESTERONE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
22. REST OF THE WORLD ESTROGEN AND PROGESTERONE MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
23. REST OF THE WORLD ESTROGEN AND PROGESTERONE MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
1. GLOBAL ESTROGEN AND PROGESTERONE MARKET SHARE BY TYPE, 2021 VS 2028 (%)
2. GLOBAL AGLEPRISTONE MARKET SHARE BY REGION, 2021 VS 2028 (%)
3. GLOBAL MIFEPRISTONE MARKET SHARE BY REGION, 2021 VS 2028 (%)
4. GLOBAL ASOPRISNIL MARKET SHARE BY REGION, 2021 VS 2028 (%)
5. GLOBAL TELAPRISTONE MARKET SHARE BY REGION, 2021 VS 2028 (%)
6. GLOBAL ULIPRISTAL ACETATE MARKET SHARE BY REGION, 2021 VS 2028 (%)
7. GLOBAL ESTROGEN AND PROGESTERONE MARKET SHARE BY DISTRIBUTION CHANNEL, 2021 VS 2028 (%)
8. GLOBAL ESTROGEN AND PROGESTERONE MARKET VIA PHARMACY SHARE BY REGION, 2021 VS 2028 (%)
9. GLOBAL ESTROGEN AND PROGESTERONE MARKET VIA HOSPITAL AND CLINICS SHARE BY REGION, 2021 VS 2028 (%)
10. GLOBAL ESTROGEN AND PROGESTERONE MARKET SHARE BY REGION, 2021 VS 2028 (%)
11. US ESTROGEN AND PROGESTERONE MARKET SIZE, 2021-2028 ($ MILLION)
12. CANADA ESTROGEN AND PROGESTERONE MARKET SIZE, 2021-2028 ($ MILLION)
13. UK ESTROGEN AND PROGESTERONE MARKET SIZE, 2021-2028 ($ MILLION)
14. FRANCE ESTROGEN AND PROGESTERONE MARKET SIZE, 2021-2028 ($ MILLION)
15. GERMANY ESTROGEN AND PROGESTERONE MARKET SIZE, 2021-2028 ($ MILLION)
16. ITALY ESTROGEN AND PROGESTERONE MARKET SIZE, 2021-2028 ($ MILLION)
17. SPAIN ESTROGEN AND PROGESTERONE MARKET SIZE, 2021-2028 ($ MILLION)
18. REST OF EUROPE ESTROGEN AND PROGESTERONE MARKET SIZE, 2021-2028 ($ MILLION)
19. INDIA ESTROGEN AND PROGESTERONE MARKET SIZE, 2021-2028 ($ MILLION)
20. CHINA ESTROGEN AND PROGESTERONE MARKET SIZE, 2021-2028 ($ MILLION)
21. JAPAN ESTROGEN AND PROGESTERONE MARKET SIZE, 2021-2028 ($ MILLION)
22. REST OF ASIA-PACIFIC ESTROGEN AND PROGESTERONE MARKET SIZE, 2021-2028 ($ MILLION)
23. REST OF THE WORLD ESTROGEN AND PROGESTERONE MARKET SIZE, 2021-2028 ($ MILLION)